Compare NPKI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | NBTX |
|---|---|---|
| Founded | 1932 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2020 |
| Metric | NPKI | NBTX |
|---|---|---|
| Price | $12.98 | $22.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $14.17 | $8.00 |
| AVG Volume (30 Days) | ★ 728.7K | 50.1K |
| Earning Date | 10-30-2025 | 09-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $259,372,000.00 | $11,930,711.00 |
| Revenue This Year | $26.96 | N/A |
| Revenue Next Year | $13.16 | $136.64 |
| P/E Ratio | $34.23 | ★ N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $4.76 | $2.82 |
| 52 Week High | $14.00 | $30.35 |
| Indicator | NPKI | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 56.36 |
| Support Level | $12.84 | $20.83 |
| Resistance Level | $13.25 | $23.77 |
| Average True Range (ATR) | 0.34 | 0.83 |
| MACD | 0.06 | 0.16 |
| Stochastic Oscillator | 79.23 | 72.52 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.